Craft

Karyopharm Therapeutics

Stock Price

$0.9

2024-07-12

Market Capitalization

$117.6 M

2024-07-12

Revenue

$146 M

FY, 2023

Karyopharm Therapeutics Summary

Company Summary

Overview
Karyopharm Therapeutics is a pharmaceutical company that discovers and develops drugs for the treatment of cancer and other major diseases. It provides small-molecule drugs that will modulate the activity of inflammation and diseases related to cell proliferation.
Type
Public
Status
Active
Founded
2008
HQ
Newton, MA, US | view all locations
Website
https://www.karyopharm.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Richard Paulson

    Richard Paulson, President, Chief Executive Officer and Director

  • Brian Austad

    Brian Austad, Senior Vice President, Pharmaceutical Sciences

  • Sharon Shacham

    Sharon Shacham, Founder and Scientific Advisory Board Member

  • James Accumanno

    James Accumanno, Chief Compliance Officer

Operating MetricsView all

Patents Issued

10

FY, 2015

LocationsView all

3 locations detected

  • Newton, MA HQ

    United States

    85 Wells Ave

  • Munich, Bayern

    Germany

    9 Franziska-Bilek-Weg

  • Giv'atayim, Tel Aviv District

    Israel

    Ariel Sharon St 4

Karyopharm Therapeutics Financials

Summary Financials

Revenue (Q1, 2024)
$33.1M
Net income (Q1, 2024)
($37.4M)
Cash (Q1, 2024)
$30.6M
EBIT (Q1, 2024)
($33.8M)
Enterprise value
$92.3M

Footer menu